MedTrace Logo

A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice

NCT00625365 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1060

Last updated 2020-11-24

Study results available
· View outcomes & findings →

Summary

The purpose of this registry study is to gather safety information on the current clinical use of and the safety of DEFINITY®

Conditions

Interventions

DRUG

DEFINITY®

DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert

Sponsors & Collaborators

  • Lantheus Medical Imaging

    lead INDUSTRY

Principal Investigators

  • Veronica Lee, MD · Lantheus Medical Imaging

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-05-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00625365 on ClinicalTrials.gov